Search

everythinglearnresearchcommunity

for

Search:↓

Pancreatic cancer pain management is inadequate due to the disease's severity and limited effectiveness of treatments.

Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.

The document suggests a possible link between hair loss and thyroid cancer, but doesn't provide definite proof.

Finasteride treats hair loss and reduces prostate cancer risk.

Hair loss at the top of the head is linked to prostate cancer, but other types of hair loss are not.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

Gene variant linked to prostate cancer, hormone levels, and hair loss.

Keratins help protect cells, aid in cancer diagnosis, and influence cancer behavior and treatment.

Understanding phenotypic plasticity is crucial for developing effective cancer therapies.

Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.

Understanding where cancer cells come from helps create better prevention and treatment methods.

Chemotherapy-induced hair loss significantly affects patients' well-being, and nurses are key in helping them cope, but more research is needed to find effective treatments.

PLD is an effective and safer alternative for treating breast cancer.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

HDR electronic brachytherapy effectively treats nonmelanoma skin cancer with good cosmetic results and minimal side effects.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Some breast cancer chemotherapy can cause permanent hair loss.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Hair and nail changes can indicate health issues, including cancer and side effects from cancer treatments.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

Scalp cooling is largely ineffective in preventing hair loss from breast cancer chemotherapy.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.